| Name | Title | Contact Details |
|---|---|---|
Matt Friedersdorf |
Chief Financial Officer | Profile |
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.
CCTC passionately serves the emotional needs of children and families at risk beginning in early childhood.
Kesin Pharma is a specialty pharmaceutical company that offers a variety of products, including unit dose drug repackaging for liquid medications and creams/ointments.
Rivers Edge Pharmaceuticals is a Suwanee, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UCS Healthcare is a healthcare organization offering a variety of services from medical to treatment.